22,314 reports of this reaction
7.8% of all TIOTROPIUM BROMIDE reports
#2 most reported adverse reaction
DYSPNOEA is the #2 most commonly reported adverse reaction for TIOTROPIUM BROMIDE, manufactured by Boehringer Ingelheim Pharmaceuticals, Inc.. There are 22,314 FDA adverse event reports linking TIOTROPIUM BROMIDE to DYSPNOEA. This represents approximately 7.8% of all 284,745 adverse event reports for this drug.
TIOTROPIUM BROMIDE has an overall safety score of 78 out of 100. Patients taking TIOTROPIUM BROMIDE who experience dyspnoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DYSPNOEA is moderately reported among TIOTROPIUM BROMIDE users, representing a notable but not dominant share of adverse events.
In addition to dyspnoea, the following adverse reactions have been reported for TIOTROPIUM BROMIDE:
The following drugs have also been linked to dyspnoea in FDA adverse event reports:
DYSPNOEA has been reported as an adverse event in 22,314 FDA reports for TIOTROPIUM BROMIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
DYSPNOEA accounts for approximately 7.8% of all adverse event reports for TIOTROPIUM BROMIDE, making it one of the most commonly reported side effect.
If you experience dyspnoea while taking TIOTROPIUM BROMIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.